Company intelligence / Profile preview
LLE Biopharma
San Diego, California, United Statesllebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LLE Biopharma is a clinical-stage biotechnology company specializing in the development of long-acting injectable (LAI) therapeutics for chronic diseases. The company utilizes its proprietary LLE-LAI platform to create sustained-release formulations of established drugs, aiming to improve patient compliance and therapeutic outcomes in conditions such as schizophrenia and opioid use disorder. Its lead programs include LLE-101, a long-acting risperidone formulation, and LLE-102, a long-acting buprenorphine formulation. LLE Biopharma operates with a focus on central nervous system (CNS) disorders and addiction medicine, maintaining research and development facilities in both the United States and China.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeLong-acting injectable
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on LLE Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLE Biopharma.